JP2012111761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012111761A5 JP2012111761A5 JP2012000042A JP2012000042A JP2012111761A5 JP 2012111761 A5 JP2012111761 A5 JP 2012111761A5 JP 2012000042 A JP2012000042 A JP 2012000042A JP 2012000042 A JP2012000042 A JP 2012000042A JP 2012111761 A5 JP2012111761 A5 JP 2012111761A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mammal
- compound
- group
- alkoxyalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000005243 carbonyl alkyl group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims 4
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims 4
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims 4
- 125000005138 alkoxysulfonyl group Chemical group 0.000 claims 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims 1
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000005335 azido alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000005019 carboxyalkenyl group Chemical group 0.000 claims 1
- -1 carboxyalkylcarbonyl Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 1
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63798704P | 2004-12-21 | 2004-12-21 | |
| US60/637,987 | 2004-12-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548450A Division JP4922946B2 (ja) | 2004-12-21 | 2005-12-21 | カンナビノイド受容体リガンドとしての３−シクロアルキルカルボニルインドール類 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012111761A JP2012111761A (ja) | 2012-06-14 |
| JP2012111761A5 true JP2012111761A5 (enExample) | 2013-04-04 |
Family
ID=36096265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548450A Expired - Fee Related JP4922946B2 (ja) | 2004-12-21 | 2005-12-21 | カンナビノイド受容体リガンドとしての３−シクロアルキルカルボニルインドール類 |
| JP2012000042A Withdrawn JP2012111761A (ja) | 2004-12-21 | 2012-01-04 | カンナビノイド受容体リガンドとしての３−シクロアルキルカルボニルインドール類 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548450A Expired - Fee Related JP4922946B2 (ja) | 2004-12-21 | 2005-12-21 | カンナビノイド受容体リガンドとしての３−シクロアルキルカルボニルインドール類 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7560481B2 (enExample) |
| EP (1) | EP1833824B1 (enExample) |
| JP (2) | JP4922946B2 (enExample) |
| CA (1) | CA2592378A1 (enExample) |
| MX (1) | MX2007007573A (enExample) |
| WO (1) | WO2006069196A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2893615B1 (fr) | 2005-11-18 | 2008-03-07 | Sanofi Aventis Sa | Derives de 3-acylindole, leur preparation et leur application en therapeutique |
| ES2645995T3 (es) * | 2006-05-31 | 2017-12-11 | Abbvie Inc. | Compuestos como ligandos del receptor cannabinoide y sus usos |
| US8841334B2 (en) * | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
| US7875640B2 (en) | 2007-03-28 | 2011-01-25 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| US7872033B2 (en) * | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| CN101711253A (zh) * | 2007-05-18 | 2010-05-19 | 雅培制药有限公司 | 用作大麻素受体配体的新化合物 |
| US8338623B2 (en) * | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US9193713B2 (en) * | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| CN101434544B (zh) * | 2007-11-15 | 2012-12-12 | 上海药明康德新药开发有限公司 | 一种4-羟甲基环己甲酸甲酯的制备方法 |
| US8846730B2 (en) * | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| EP2428507B1 (en) * | 2008-09-16 | 2015-10-21 | AbbVie Bahamas Ltd. | Cannabinoid receptor ligands |
| PA8854001A1 (es) * | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
| FR2950055A1 (fr) | 2009-09-17 | 2011-03-18 | Sanofi Aventis | Derives de 3-amino-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique |
| DE102011002934A1 (de) * | 2011-01-20 | 2012-07-26 | Bayer Schering Pharma Ag | CB2 Agonisten zur Behandlung und Vorbeugung der Endometriose |
| FR2983859B1 (fr) | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
| GB201305061D0 (en) * | 2013-03-20 | 2013-05-01 | Randox Lab | Immunoassay for UR-144,XLR-11,metabolites and derivatives |
| US20240174606A1 (en) * | 2021-09-03 | 2024-05-30 | Shenzhen 01 Life Science And Technology Co., Ltd. | Indole compounds, and preparation methods, and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3557142A (en) * | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
| US4885295A (en) * | 1984-08-06 | 1989-12-05 | Sterling Drug Inc. | Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles |
| US4978664A (en) * | 1984-08-06 | 1990-12-18 | Sterling Drug Inc. | 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indole pharmaceutical compositions |
| DE3825840A1 (de) * | 1988-07-29 | 1990-02-01 | Basf Ag | Dihydrodibenzofuranderivate und diese verbindungen enthaltende fungizide |
| US4973587A (en) * | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| US5013837A (en) * | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| EP0648208A1 (en) * | 1993-04-05 | 1995-04-19 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives as testosterone 5 alpha-reductase inhibitors |
| EP1221307B1 (en) | 1994-07-08 | 2010-02-17 | ev3 Inc. | System for performing an intravascular procedure |
| FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| US6358992B1 (en) * | 1998-11-25 | 2002-03-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
| MXPA02005101A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Derivados de indol canabimimeticos. |
| US6653304B2 (en) * | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| GB0010437D0 (en) | 2000-04-28 | 2000-06-14 | Darwin Discovery Ltd | Process |
| FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| EP1363632B1 (en) | 2001-01-29 | 2010-08-25 | The University of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
| FR2847899B1 (fr) | 2002-11-29 | 2006-04-28 | Sanofi Synthelabo | Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique |
-
2005
- 2005-12-21 WO PCT/US2005/046480 patent/WO2006069196A1/en not_active Ceased
- 2005-12-21 CA CA002592378A patent/CA2592378A1/en not_active Abandoned
- 2005-12-21 US US11/315,862 patent/US7560481B2/en active Active
- 2005-12-21 EP EP05855099.7A patent/EP1833824B1/en not_active Expired - Lifetime
- 2005-12-21 JP JP2007548450A patent/JP4922946B2/ja not_active Expired - Fee Related
- 2005-12-21 MX MX2007007573A patent/MX2007007573A/es active IP Right Grant
-
2009
- 2009-02-13 US US12/370,727 patent/US7750039B2/en not_active Expired - Fee Related
-
2010
- 2010-06-14 US US12/815,163 patent/US20110065685A1/en not_active Abandoned
-
2012
- 2012-01-04 JP JP2012000042A patent/JP2012111761A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012111761A5 (enExample) | ||
| JP2010527373A5 (enExample) | ||
| RU2737190C2 (ru) | Ингибиторы репликации вируса гриппа, способы их применения и использование | |
| JP2016528301A5 (enExample) | ||
| JP2011521911A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP2013516393A5 (enExample) | ||
| JP2019537570A5 (enExample) | ||
| JP2012041349A5 (enExample) | ||
| JP2010523681A5 (enExample) | ||
| JP2015515961A5 (enExample) | ||
| JP2013510124A5 (enExample) | ||
| JP2017538721A5 (enExample) | ||
| JP2013508382A5 (enExample) | ||
| JP2011006480A5 (enExample) | ||
| JP2013544261A5 (enExample) | ||
| JP2017505762A5 (enExample) | ||
| JP2015503617A5 (enExample) | ||
| JP2010241830A5 (enExample) | ||
| JP2013539789A5 (enExample) | ||
| JP2007509058A5 (enExample) | ||
| JP2011132222A5 (enExample) | ||
| JP2015134783A (ja) | ５，６−ジヒドロ−１ｈ−ピリジン−２−オン化合物 | |
| NZ592961A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |